Research Guide · KLOW80

What is KLOW80?

A four-component research composite combining GHK-Cu (50mg), TB-500, BPC-157 and KPV (10mg each) for broad multi-pathway tissue regeneration, anti-inflammatory and dermal repair research.

Updated September 2026 Research Use Only 12 min read

What is KLOW80

A research composite delivering four complementary peptides totalling 80mg in one vial, with GHK-Cu as the dominant component.

Composite Formulation

KLOW80 is a four-component research composite at 80mg total: GHK-Cu (50mg) + TB-500 (10mg) + BPC-157 (10mg) + KPV (10mg). GHK-Cu accounts for 62.5% of the mass, making this a copper-tripeptide-dominant composite augmented by the TR-3 peptide triad.

Mechanistic Rationale

Combines GHK-Cu’s collagen synthesis, copper-dependent regenerative signalling and antioxidant effects with the cellular migration (TB-500), angiogenesis (BPC-157), and NF-κB anti-inflammatory (KPV) pathways. Targets four parallel axes of tissue regeneration in one preparation.

Research Use Only

Strictly for in-vitro laboratory research and animal model studies. Not approved for human consumption or therapeutic application. Composite formulation is a vendor research convenience.

Component Mechanisms

Four peptides, four complementary mechanisms.

GHK-Cu (50mg) — Dominant Copper Tripeptide

Glycyl-L-histidyl-L-lysine bound to copper(II); naturally occurring tripeptide. Drives collagen COL1A1/COL1A2 transcription, modulates matrix metalloproteinases, exerts copper-dependent SOD-like antioxidant activity, and stimulates angiogenesis. At 50mg per vial, GHK-Cu is the dominant pharmacological signal in KLOW80 (Pickart et al., 2012).

TB-500 (10mg) — Cellular Migration via G-actin Sequestration

17-amino acid Thymosin Beta-4 fragment containing the active actin-binding domain. Sequesters G-actin monomers, regulating cytoskeletal dynamics for cellular migration to injury sites and progenitor cell recruitment (Crockford et al., 2010; Goldstein et al., 2012).

BPC-157 (10mg) — Angiogenesis & Cytoprotection

15-amino acid pentadecapeptide derived from human gastric juice. Promotes angiogenesis via VEGF upregulation and nitric oxide synthase modulation; supports tendon, ligament, and gut barrier repair (Sikiric et al., 2014).

KPV (10mg) — NF-κB Anti-inflammatory

Tripeptide alpha-MSH 11–13 fragment (Lys-Pro-Val). PepT1-mediated cellular entry; intracellular NF-κB inhibition; suppresses TNF-α, IL-1β, IL-6, IL-8. Provides inflammatory tone control to complement the regenerative components (Brzoska et al., 2008).

Combined Pathway Coordination

The four axes together provide: collagen matrix synthesis (GHK-Cu), cellular recruitment (TB-500), local angiogenic priming (BPC-157), and NF-κB inflammatory control (KPV). KLOW80 is a research model for broad-spectrum regenerative pharmacology incorporating both pro-repair and inflammation-modulating signals.

KLOW80 vs Related Composites

How KLOW80 compares to GLOW70, TR-3, TR-2, and single-peptide protocols.

Composite

Components

Distinguishing Feature

KLOW80

GHK-Cu 50mg + TB-500/BPC-157/KPV 10mg ea (80mg)

Most comprehensive: copper signalling + repair triad + anti-inflammatory

GLOW70

GHK-Cu + BPC-157 + TB-500 (70mg)

Lacks KPV anti-inflammatory third axis; dermal regeneration focus

TR-3

TB-500 + BPC-157 + KPV (30mg)

Lacks GHK-Cu copper/collagen signalling; tissue repair + inflammation control

TR-2

BPC-157 + TB-500 (20-40mg)

Simplest two-pathway composite; no copper or anti-inflammatory layer

Single GHK-Cu

GHK-Cu alone

Pure copper signalling without recruitment, vascularisation, or inflammation modulation

Research Context: KLOW80’s GHK-Cu dominance (62.5% of mass) makes it primarily a copper-driven regenerative composite, with the supporting TR-3 triad providing complementary recruitment, vascularisation, and anti-inflammatory pathways. Suited to research models requiring broad mechanism coverage in a single preparation.

Key Research Applications

Primary research domains for KLOW80.

Dermal Regeneration with Inflammation Control

GHK-Cu’s collagen synthesis combined with KPV’s NF-κB inhibition addresses both regeneration and inflammation in atopic, photoaged, or chronically inflamed skin research models. TB-500/BPC-157 contribute cellular and vascular support.

Complex Wound Healing Models

Chronic wounds with inflammation, infection risk, and impaired vascularisation benefit from broad-spectrum multi-pathway intervention. KPV’s antimicrobial activity adds research interest in infected wound contexts.

Anti-ageing Skin Protocols

GHK-Cu has decades of skin anti-ageing research; KLOW80 provides a research model for combined collagen induction, cellular migration support, and inflammation modulation in chronologically aged skin models.

Regenerative Biology with Mucosal/Anti-inflammatory Components

KPV’s intestinal targeting via PepT1 makes the composite of interest in mucosal regeneration models, particularly in IBD where inflammation control and barrier repair coexist.

Multi-pathway Repair Pharmacology

As a research tool, KLOW80 enables investigation of how four parallel-pathway interventions compare to sequential or simpler composites — critical for designing rational combination therapies in regenerative biology.

Quick Reference Specifications

Composite parameters.

P · 01

Designation

KLOW80 (4-component research composite)

P · 02

Components

GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg + KPV 10mg

P · 03

Total Mass

80mg per vial (lyophilised)

P · 04

Component MWs

GHK-Cu ~402 Da; TB-500 ~889 Da; BPC-157 ~1,419 Da; KPV ~342 Da

P · 05

CAS Numbers

GHK-Cu 89030-95-5; BPC-157 137525-51-0; KPV 67727-97-3; TB-500 (Tβ4 fragment) per supplier

P · 06

Purity

>99% HPLC per component

P · 07

Format

Lyophilised composite powder

P · 08

Dominant Component

GHK-Cu at 62.5% of mass

P · 09

Storage (Lyophilised)

2–8°C; protect from light

P · 10

Storage (Reconstituted)

2–8°C with bacteriostatic water; stable 2–4 weeks

Reconstitution & Storage

Multi-peptide composite handling.

Reconstitution

Reconstitute with sterile bacteriostatic water (0.9% NaCl with 0.9% benzyl alcohol). Use sterile syringes; gentle dissolution with extended swirling (3–5 minutes) due to the four-component formulation. Avoid shaking. Disposable pen format requires no reconstitution.

Storage Timeline

Reconstituted KLOW80 maintains bioactivity for 2–4 weeks at 2–8°C. The copper-bound GHK-Cu drives a faint blue-green colour in solution, expected and stable. Avoid freeze-thaw cycles; protect from light.

Quality Control

Reconstituted solution should be clear with a faint blue-green tint from the GHK-Cu copper complex. Cloudiness, brown discolouration, precipitate, or strong colour change indicates degradation or copper precipitation; discard.

Handling Best Practices

Maintain consistent refrigeration; document reconstitution date; aliquot for extended programmes; use fresh sterile needles per withdrawal; never freeze-thaw; equilibrate to room temperature before use; discard solutions older than 4 weeks.

Component Evidence at a Glance

What the published literature supports for each ingredient.

GHK-Cu

Collagen & matrix synthesis

Stimulated collagen synthesis in fibroblasts at nanomolar concentrations; widely reviewed for skin-regeneration pathways. Human data: small topical cosmetic studies.^1–2

TB-500

Cell migration & wound closure

Full-length Tβ4 accelerated re-epithelialisation in rat wounds; the LKKTETQ actin-binding motif used in TB-500 reproduced key pro-angiogenic effects in vitro. No human data for the fragment.^6–8

BPC-157

Angiogenesis & tendon repair

Rodent tendon, muscle and ischaemia models, including FAK–paxillin and VEGFR2–Akt–eNOS signalling. Human data: a two-participant IV safety pilot (2025).^3–5

KPV

NF-κB anti-inflammatory

PepT1-mediated uptake reduced colitis in DSS and TNBS mouse models, including with oral nanoparticle formulations. No human studies.^9–10

Regulatory & Research Status

Component status in 2026.

APR 26

FDA Category 2 removal

BPC-157, TB-500, KPV and injectable GHK-Cu were among twelve peptides removed from the US FDA’s Category 2 compounding list. This is not an approval.

JUL 26

Advisory committee votes

The FDA’s Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend BPC-157, TB-500 and KPV individually for the 503A bulks list. GHK-Cu was not reviewed. The votes are non-binding and do not cover combination products.

SPORT

WADA 2026

BPC-157 (S0) and TB-500 (S2) are prohibited at all times.

Evidence Quality & Limitations

No peer-reviewed study has tested KLOW80 as a combination. The rationale rests on each component’s individual evidence and complementary mechanisms, so “synergy” is a hypothesis to test rather than an established finding. Component ratios reflect the product formulation rather than published dose-response work, and the stability and compatibility of the peptides stored together in one solution have not been characterised in the literature. Nearly all component data are preclinical.

References

Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238:343–6. PubMed
Pickart L, et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PubMed
Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774–80. PubMed
Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95:323–33. PubMed
Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20–4. PubMed
Malinda KM, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113:364–8. PubMed
Philp D, et al. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17:2103–5. PubMed
Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. J Chromatogr A. 2012;1265:57–69. PubMed
Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134:166–78. PubMed
Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25:1628–40. PubMed

⚠ Research Use Only. The compounds discussed in this guide are intended strictly for in-vitro laboratory research. Not for human consumption, therapeutic use, or veterinary application. Researchers must comply with all applicable local regulations.